Revision 1

Store at -20C

#13206

CRABP1 (D5W9A) Rabbit mAb

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355) orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H M	Endogenous	15	Rabbit IgG	#P29762	1381

Product Usage Information

Application	Dilution
Western Blotting	1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

CRABP1 (D5W9A) Rabbit mAb recognizes endogenous levels of total CRABP1 protein. This antibody does not cross-react with other intracellular lipid-binding protein family members, CRBP1 and CRBP2.

Species predicted to react based on 100% sequence homology

Rat, Chicken, Bovine

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human CRABP1 protein.

Background

Vitamin A gives rise to multiple species of biologically active lipophilic metabolites, known as retinoids, which play a critical role in numerous physiological processes such as vision and embryonic development. Intracellularly, all-*trans* retinoic acid is bound with high affinity to either cellular retinoic acid-binding protein 1 (CRABP1) or cellular retinoic acid-binding protein 2 (CRABP2), which aids in its solubilization within the aqueous cytosolic compartment. Belonging to the intracellular lipid-binding protein family (iLBP), the human CRABPs are 74% identical at the protein level and each CRABP is highly conserved across multiple species. Research studies have shown that knockout of *Crabp1* is not lethal but results in defects in limb development (1), suggesting that CRABP1 plays a role in establishing retinoic acid concentration gradients in the developing limb bud. Although it remains unclear how CRABP1 may regulate the formation of retinoic acid gradients *in vivo*, research studies have suggested that CRABP1 can enhance the activities of intracellular retinoic acid-metabolizing enzymes, thus blunting cellular responses to retinoic acid (2-4).

Background References

1. Lampron, C. et al. (1995) *Development* 121, 539-48.
2. Fujii, H. et al. (1997) *EMBO J* 16, 4163-73.
3. Boylan, J.F. and Gudas, L.J. (1992) *J Biol Chem* 267, 21486-91.
4. Boylan, J.F. and Gudas, L.J. (1991) *J Cell Biol* 112, 965-79.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human **M:** Mouse

Trademarks and Patents

Limited Uses

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.